ProPhase Labs

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

ProPhase Labs achieves record revenues, Nebula Genomics poised for growth

ProPhase Labs delivered strong financial performance in 2022, showcasing a successful transformation and diversification strategy.
The company's subsidiaries, particularly Nebula Genomics and BE-Smart, offer significant growth potential and differentiation in their respective markets.
While challenges like declining COVID testing trends and financial impacts exist, strategic opportunities and efficient management position ProPhase Labs for continued success.

ProPhase Labs prioritizes value-building over earnings, eyes global growth

ProPhase Labs is strategically focusing on long-term value creation through its diverse business segments.
While facing challenges in COVID testing and profitability, the company is optimistic about revenue growth from key assets.
Opportunities in precision medicine, cancer compounds, and global expansion present avenues for future growth.

ProPhase Labs shifts focus to genetic testing, eyes global expansion

ProPhase Labs is strategically pivoting towards genetic testing with Nebula Genomics, focusing on advanced laboratory capabilities and potential revenue generation. Despite revenue declines in Q2, the company remains optimistic about future growth prospects and is actively exploring financing options for expansion.

ProPhase Labs anticipates substantial growth with innovative healthcare solutions

ProPhase Labs is strategically positioned for growth with strong demand for its subsidiaries and innovative healthcare solutions in development.
While facing challenges in market conditions and revenue guidance, the company's focus on expansion and efficiency drives optimism for future performance.
Opportunities lie in revenue and profitability increases, potential IPOs, and advancements in esophageal cancer testing techniques and therapeutics.
Investors are encouraged to consider the long-term potential of ProPhase Labs as it navigates challenges and capitalizes on growth prospects.

ProPhase Labs excels in Q4, eyes revenue growth and strategic partnerships

ProPhase Labs showcased strong historical performance, profitable business segments, and strategic growth initiatives. The company is poised for substantial revenue growth through key contracts, innovative product offerings, and expansion into new markets. Challenges in short-term profitability and regulatory restrictions are being addressed while focusing on long-term value creation and growth potential.

ProPhase Labs (PRPH) reports strong performance and explores strategic opportunities

ProPhase Labs (PRPH) showcased strong historical performance, highlighted key initiatives like Pharmaloz and Nebula Genomics, and emphasized the potential for liquidity events. Challenges include revenue growth uncertainty and transparency concerns over share count increase.

ProPhase Labs strategizes for growth amidst seasonality and liquidity concerns

ProPhase Labs is navigating mixed performance with a focus on strategic initiatives, liquidity management, and maximizing shareholder value.
The company's strengths lie in its leadership team, growth potential in precision medicine, and plans for mitigating seasonality in revenue streams.
Challenges include seasonality impact, liquidity concerns, and the need for successful execution of strategic alternatives for Pharmaloz.
Opportunities exist in partnerships for Pharmaloz, growth potential in precision medicine, and anticipated revenue growth in the upcoming quarters.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GARDEN CITY, NY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Q4 Investor Summit Conference, which is being held virtually from November 16 – 17, 2021.

ProPhase Labs to Present at the Q4 Investor Summit Conference

GARDEN CITY, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, will hold a conference call on Friday, November 12, 2021 at 11:00 a.m. Eastern time to discuss its results for the third quarter ended September 30, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Third Quarter 2021 Financial Results Conference Call on Friday, November 12, 2021 at 11:00 a.m. Eastern Time

As vaccine mandates are rejected, Covid-19 testing volumes should increase.

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Garden City, NY, Oct. 13, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified biotech and genomics company, today announces that it expects its Q3 2021 COVID-19 testing revenues to be lower than its Q2 2021 testing revenues given the overall lower levels of COVID-19 testing during the summer months. However, based on the recent uptick in COVID-19 testing (due in part to various government and employer-imposed mandates) and the Company's growing customer base for testing services, the Company anticipates Q4 2021 COVID-19 testing revenues to be in-line the record levels achieved in Q1 of this year, despite recently decreasing COVID-19 positivity rates.

ProPhase Labs Provides Business Update

GARDEN CITY, NY, Oct. 06, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will be presenting virtually at the 14th Annual LD Micro Main Event Conference.

ProPhase Labs to Present at the LD Micro Main Event Conference

GARDEN CITY, NY, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, today announced that Chairman and CEO Ted Karkus is scheduled to present at the following investor conferences:

ProPhase Labs to Present at Two Upcoming August Conferences

ProPhase Labs' (PRPH) CEO Ted Karkus on Q2 2021 Results - Earnings Call Transcript

Shares of ProPhase Labs (NASDAQ:PRPH) rose 3.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 1000.00% over the past year to ($0.09), which missed the estimate of $0.33.

Recap: ProPhase Labs Q2 Earnings

Company Provides Update on Significant Resurgence in Covid testing and Additional Insights into Previously Announced Nebula Genomics Acquisition

ProPhase Labs Announces Financial Results for the Quarter Ended June 30, 2021

ProPhase Labs Inc (NASDAQ: PRPH) has acquired privately-held Nebula Genomics for approximately $14.6 million in a combination of stock and cash.  Prophase will integrate Nebula's whole genome sequencing services with its clinical diagnostic testing services.

ProPhase Labs Acquires Whole Genome Sequencing Firm For $14.5M

GARDEN CITY, NY , Aug. 09, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Friday, August 13, 2021 at 11:00 a.m. Eastern time to discuss its results for the second quarter ended June 30, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host Second Quarter 2021 Financial Results Conference Call on Friday, August 13, 2021 at 11:00 a.m. Eastern Time

GARDEN CITY, NY, July 12, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announced that Chief Executive Officer Ted Karkus will present a corporate overview at the Access to Giving Virtual Investor Conference being held on July 13 - 15, 2021.

ProPhase Labs to Present at the Access to Giving Virtual Investor Conference on July 15, 2021

GARDEN CITY, NY, July 01, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, announced today that it has retained CORE IR, a leading investor relations, public relations and strategic advisory firm, to assist the Company with investor relations, public relations and shareholder communications services.

ProPhase Labs Engages CORE IR for Investor Relations, Public Relations and Shareholder Communications Services

There is concern that new Covid-19 variants are spreading and that they have the possibility to escape current vaccinations.

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

GARDEN CITY, NY, June 28, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a diversified medical science and technology company, today announces that it has been added to the Russell Microcap Index. This milestone became effective at the conclusion of the 2021 Russell Indexes' annual reconstitution, which occurred immediately following the U.S. market opening today, June 28, 2021.

ProPhase Labs Added to the Russell Microcap Index

ProPhase Precision Medicine, Inc. and ProPhase Global Healthcare , Inc. to Expand Opportunities in Genomics and International Testing Services

ProPhase Labs Diversifies with Formation of Genomics and Global Healthcare Subsidiaries

CEO Ted Karkus to Present at Conference on Thursday , June 10 th , 2021

ProPhase Labs to Present at LD Micro Invitational XI Virtual Conference

ProPhase Labs' (PRPH) CEO Ted Karkus on Q1 2021 Results - Earnings Call Transcript

The stock price of ProPhase Labs Inc (NASDAQ: PRPH) increased 14.94% (from $5.22 to $6) pre-market. This is why it happened.

PRPH Stock: 14.94% Increase (From $5.22 To $6) Pre-Market Explanation

GARDEN CITY, NY, April 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, will hold a conference call on Thursday, May 13, 2021 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call.

ProPhase Labs to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time

ProPhase Labs, Inc. (PRPH) CEO Ted Karkus on Q4 2020 Results - Earnings Call Transcript

Recent Acquisition of Digital COVID-19 Vaccination and Testing “Passport” Transforms the Company's Portal Into a Universal Digital Certificate Solution and Uniquely Positions Company for Re-Opening Phase of Pandemic

ProPhase Labs Reports Fourth Quarter and Full Year 2020 Financial Results

The stock price of  ProPhase Labs, Inc. (NASDAQ: PRPH) increased by over 10% pre-market. This is why it happened.

PRPH Stock Price Increased Over 10% Pre-Market: Why It Happened

Shares of ProPhase Labs Inc (NASDAQ: PRPH), a consumer healthcare and diagnostics company, jumped 32% in the extended session on Tuesday. What Happened: ProPhase said on Tuesday it has acquired mobile app company VaccTrack, which confirms a user has been vaccinated against COVID-19, for an undisclosed amount.

Why ProPhase Labs Shares Jumped 32% Today

New Reporting App Simplifies Documentation of User Vaccination and Covid Testing Statue – Easily Enables Clear Access to Air/Rail/Bus Travel, Concert & Sporting Events

News for ProPhase Labs Stock (PRPH)